Pfizer and Astellas announce extended survival data from EV-302 trial in advanced urothelial cancer EP News Bureau Feb 11, 2025 Additional follow-up from the Phase 3 study shows sustained overall survival benefit of enfortumab vedotin and pembrolizumab…
